### 2.2.1 In vitro and physicochemical data

A literature search was performed to collect available information on physicochemical properties of pitavastatin. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**           | **Unit** | **Value** | Source                               | **Description**                                              |
| :---------------------- | -------- | --------- | ------------------------------------ | ------------------------------------------------------------ |
| MW                      | g/mol    | 421.46    | [Yoshikado 2018](#5-references)        | Molecular weight                                             |
| pK<sub>a</sub> (acid)   |          | 4.24      | [Yoshikado 2018](#5-references)         | acid dissociation constant of conjugate acid                 |
| pK<sub>a</sub> (base)   |          | 4.68      | [Yoshikado 2018](#5-references)         | acid dissociation constant of conjugate base                 |
| Solubility (pH7.4)      | mg/mL    | 0.004     | [DrugBank](#5-references)              | Aqueous Solubility in pH 7.4                 |
| logP                    |          | 1.92     | [Yoshikado 2018](#5-references)         | Partition coefficient between octanol and water              |
|                         |          |2.91      | [Kimoto 2022](#5-references)         | Partition coefficient between octanol and water              |
| fu                      | %        | 0.52       | [Yoshikado 2018](#5-references)   | Fraction unbound in plasma                                   |
| K<sub>m</sub> OATP1B1   | µmol/L   | 0.77     | [Duan 2017](#5-references)            | OATP1B1 Michaelis-Menten constant                             |
| K<sub>m</sub> BCRP      | µmol/L   | 2.02       | Assumed same as for Rosuvastatin| BCRP Michaelis-Menten                                    |
| Lint80 Dissolution time | min      | 30     | [Cho 2024](#5-references)          | Dissolution time until 80% of drug is dissolved              |
| GFR fraction            | fraction | 0     | [Mochizuki 2022](#5-references)        | glomerular filtration rate              |

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on pitavastatin in adults. 

The following publications were found in adults for model building:

| Publication                   | Arm / Treatment / Information used for model building        |
| :---------------------------- | :----------------------------------------------------------- |
| [Kimoto 2022](#5-references)   | Plasma PK profiles in healthy subjects after single iv infusion (1h) of 2 mg pitavastatin and oral administration of 2 and 4 mg pitavastatin|
| [Mori 2020](#5-references)  | Plasma PK profiles in healthy subjects after single oral administration of 0.2 mg pitavastatin |
| [Takehara 2018](#5-references) | Plasma PK profiles in healthy subjects after single oral administration of 0.2 mg pitavastatin|
| [Lou 2015](#5-references)   | Plasma PK profiles in healthy subjects after single oral administration of 1, 2 and 4 mg pitavastatin |
| [Chen 2013](#5-references)   | Plasma PK profiles in healthy subjects after single oral administration of 4 mg pitavastatin |
| [Prueksaritanont 2014](#5-references)   | Plasma PK profiles in healthy subjects after single oral administration of 1 mg pitavastatin |


The following dosing scenarios were simulated and compared to respective data for model verification:

| Scenario                                                     | Data reference                       |
| ------------------------------------------------------------ | ------------------------------------ |
| po 2 mg in 3 different SLCO1B1 genotypes                     |[Ieiri 2007](#5-references)           |


